» Articles » PMID: 25389045

Epidermal Growth Factor Attenuates Tubular Necrosis Following Mercuric Chloride Damage by Regeneration of Indigenous, Not Bone Marrow-derived Cells

Overview
Journal J Cell Mol Med
Date 2014 Nov 13
PMID 25389045
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

To assess effects of epidermal growth factor (EGF) and pegylated granulocyte colony-stimulating factor (P-GCSF; pegfilgrastim) administration on the cellular origin of renal tubular epithelium regenerating after acute kidney injury initiated by mercuric chloride (HgCl2 ). Female mice were irradiated and male whole bone marrow (BM) was transplanted into them. Six weeks later recipient mice were assigned to one of eight groups: control, P-GCSF+, EGF+, P-GCSF+EGF+, HgCl2 , HgCl2 +P-GCSF+, HgCl2 +EGF+ and HgCl2 +P-GCSF+EGF+. Following HgCl2 , injection tubular injury scores increased and serum urea nitrogen levels reached uraemia after 3 days, but EGF-treated groups were resistant to this acute kidney injury. A four-in-one analytical technique for identification of cellular origin, tubular phenotype, basement membrane and S-phase status revealed that BM contributed 1% of proximal tubular epithelium in undamaged kidneys and 3% after HgCl2 damage, with no effects of exogenous EGF or P-GCSF. Only 0.5% proximal tubular cells were seen in S-phase in the undamaged group kidneys; this increased to 7-8% after HgCl2 damage and to 15% after addition of EGF. Most of the regenerating tubular epithelium originated from the indigenous pool. BM contributed up to 6.6% of the proximal tubular cells in S-phase after HgCl2 damage, but only to 3.3% after additional EGF. EGF administration attenuated tubular necrosis following HgCl2 damage, and the major cause of this protective effect was division of indigenous cells, whereas BM-derived cells were less responsive. P-GCSF did not influence damage or regeneration.

Citing Articles

Bioartificial Kidneys.

Corridon P, Ko I, Yoo J, Atala A Curr Stem Cell Rep. 2020; 3(2):68-76.

PMID: 33005562 PMC: 7526744. DOI: 10.1007/s40778-017-0079-3.


The Effect of Shen Qi Wan Medicated Serum on NRK-52E Cells Proliferation and Migration by Targeting Aquaporin 1 (AQP1).

He Y, Bao Y, Chen H, Chen Y, Zhou X, Yang Y Med Sci Monit. 2020; 26:e922943.

PMID: 32491998 PMC: 7293146. DOI: 10.12659/MSM.922943.


Potential targeted therapy and diagnosis based on novel insight into growth factors, receptors, and downstream effectors in acute kidney injury and acute kidney injury-chronic kidney disease progression.

Gao L, Zhong X, Jin J, Li J, Meng X Signal Transduct Target Ther. 2020; 5(1):9.

PMID: 32296020 PMC: 7018831. DOI: 10.1038/s41392-020-0106-1.


Isolation of Mesenchymal Stem Cells from Human Deciduous Teeth Pulp.

Tsai A, Hong H, Lin W, Fu J, Chang C, Wang I Biomed Res Int. 2017; 2017:2851906.

PMID: 28377925 PMC: 5362703. DOI: 10.1155/2017/2851906.


Progression of chronic kidney disease: too much cellular talk causes damage.

Gewin L, Zent R, Pozzi A Kidney Int. 2016; 91(3):552-560.

PMID: 27773427 PMC: 5313325. DOI: 10.1016/j.kint.2016.08.025.


References
1.
Bashir O, Fitzgerald A, Berlanga-Acosta J, Playford R, Goodlad R . Effect of epidermal growth factor administration on intestinal cell proliferation, crypt fission and polyp formation in multiple intestinal neoplasia (Min) mice. Clin Sci (Lond). 2003; 105(3):323-30. DOI: 10.1042/CS20030023. View

2.
Yen T, Yang H, Yeh Y, Chu P, Wen C, Fu J . Aliskiren attenuates proteinuria in mice with lupus nephritis by a blood pressure-independent mechanism. Lupus. 2012; 22(2):180-9. DOI: 10.1177/0961203312471871. View

3.
Togel F, Isaac J, Westenfelder C . Hematopoietic stem cell mobilization-associated granulocytosis severely worsens acute renal failure. J Am Soc Nephrol. 2004; 15(5):1261-7. DOI: 10.1097/01.asn.0000123692.01237.0a. View

4.
Morigi M, Imberti B, Zoja C, Corna D, Tomasoni S, Abbate M . Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. J Am Soc Nephrol. 2004; 15(7):1794-804. DOI: 10.1097/01.asn.0000128974.07460.34. View

5.
Rowinsky E, Schwartz G, Gollob J, Thompson J, Vogelzang N, Figlin R . Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol. 2004; 22(15):3003-15. DOI: 10.1200/JCO.2004.11.061. View